CA2726939A1 - 4,6-diphenylpyrid-2-ones against cancer - Google Patents

4,6-diphenylpyrid-2-ones against cancer Download PDF

Info

Publication number
CA2726939A1
CA2726939A1 CA2726939A CA2726939A CA2726939A1 CA 2726939 A1 CA2726939 A1 CA 2726939A1 CA 2726939 A CA2726939 A CA 2726939A CA 2726939 A CA2726939 A CA 2726939A CA 2726939 A1 CA2726939 A1 CA 2726939A1
Authority
CA
Canada
Prior art keywords
lower alkyl
compound
independently
halo
remainder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2726939A
Other languages
English (en)
French (fr)
Inventor
Gerard Andrew Potter
Philip Huxley
Kenneth James Beresford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incanthera Therapeutics Ltd
Original Assignee
Spear Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spear Therapeutics Ltd filed Critical Spear Therapeutics Ltd
Publication of CA2726939A1 publication Critical patent/CA2726939A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2726939A 2008-06-04 2009-06-04 4,6-diphenylpyrid-2-ones against cancer Abandoned CA2726939A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0810228.7A GB0810228D0 (en) 2008-06-04 2008-06-04 Novel compounds
EP0810228.7 2008-06-04
PCT/EP2009/004005 WO2009146910A1 (en) 2008-06-04 2009-06-04 4, 6-diphenylpyrid-2-0nes against cancer

Publications (1)

Publication Number Publication Date
CA2726939A1 true CA2726939A1 (en) 2009-12-10

Family

ID=39638174

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2726939A Abandoned CA2726939A1 (en) 2008-06-04 2009-06-04 4,6-diphenylpyrid-2-ones against cancer

Country Status (7)

Country Link
US (2) US8236827B2 (enExample)
EP (1) EP2310370A1 (enExample)
JP (1) JP2011521986A (enExample)
AU (1) AU2009254176A1 (enExample)
CA (1) CA2726939A1 (enExample)
GB (1) GB0810228D0 (enExample)
WO (1) WO2009146910A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058550A2 (en) * 2010-10-29 2012-05-03 Fox Chase Cancer Center Methods for screening compounds for capability to inhibit premalignant squamous epithelial cell progression to a malignant state
US9101603B2 (en) 2010-11-30 2015-08-11 Institute For Cancer Research Targeting of CYP1B1 in the treatment of head and neck cancer and lung cancer
CN103387574A (zh) * 2012-05-07 2013-11-13 北京以岭药业有限公司 一种表小檗碱的合成方法
CN107591180A (zh) * 2016-07-07 2018-01-16 中芯国际集成电路制造(上海)有限公司 非挥发性存储器及其读取数据的方法
EP3484864A1 (en) * 2016-07-13 2019-05-22 Centre National de la Recherche Scientifique - CNRS Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
US7910742B2 (en) * 2005-09-29 2011-03-22 Abbott Laboratories Survivin inhibitors
US8242129B2 (en) 2007-04-25 2012-08-14 Exelixis, Inc. 6-phenylpyrimidinones as PIM modulators

Also Published As

Publication number Publication date
US20130023567A1 (en) 2013-01-24
GB0810228D0 (en) 2008-07-09
US20100168180A1 (en) 2010-07-01
US8236827B2 (en) 2012-08-07
AU2009254176A1 (en) 2009-12-10
JP2011521986A (ja) 2011-07-28
WO2009146910A8 (en) 2011-04-07
EP2310370A1 (en) 2011-04-20
WO2009146910A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
US20250295789A1 (en) Treatment or prophylaxis of proliferative conditions
JP2024526311A (ja) Ｋａｔ６阻害剤としての化合物
WO2003026664A1 (en) 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
JP3080405B2 (ja) アミノスチルバゾール誘導体及び医薬
US20130023567A1 (en) Novel Compounds
JP4805166B2 (ja) アロイルフランおよびアロイルチオフェン
JP2024073414A (ja) ゲムシタビン誘導体の新規小分子薬物コンジュゲート
WO2012073184A1 (en) Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases
WO2012149048A1 (en) Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of lyp
JP2023504523A (ja) 疾患処置に使用するための大環状分子
KR101739362B1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
KR101644778B1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
WO2021019051A1 (en) Inhibitors of human atgl
JP2021512953A (ja) ゲムシタビンモノホスフェートの小分子薬物コンジュゲート
AU2013203591B2 (en) Treatment or prophylaxis of proliferative conditions
WO2022262671A1 (zh) 杂环大环化合物及其医药用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140529

FZDE Dead

Effective date: 20160606